News
Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma, ...
A three-year-old girl has become the youngest patient in the UK to receive a groundbreaking gene therapy for a rare, ...
Gunreet Kaur has a rare inherited condition which can be fatal. A child with a life-threatening disease has become the youngest in the UK to receive a groundbreaking gene therapy. Three-year-old ...
IFINWIL®: now approved in Switzerland1Nine out of 10 cases of neuroblastoma occur in children under the age of five2The average survival rate of children with HRNB is only 50%2UXBRIDGE, England ...
3d
DISABLED ENTREPRENEUR UK on MSNA Three-Year-Old Receives Groundbreaking Gene TherapyIn a historic medical breakthrough, a three-year-old child has become the youngest patient ever to receive a revolutionary ...
Type 1 diabetes (T1D) is an autoimmune condition where the immune system destroys insulin-producing β-cells in the pancreas. Yet, not all patients lose insulin function at the same pace. Understanding ...
Anti-glutamic acid decarboxylase (GAD) antibodies are described in stiff-person syndrome and also in other neurological syndromes, including cerebellar ataxia and epilepsy. This paper reports the case ...
Abstract. We have shown that ornithine decarboxylase (ODC) overexpression in the skin of TG.AC v-Ha-ras transgenic mice induces the formation of spontaneous skin carcinomas. Treatment of ODC/Ras ...
Ornithine decarboxylase (ODC) is a pyridoxal 5‘-phosphate (PLP) dependent enzyme that catalyzes the decarboxylation of l-Orn to putrescine, a rate-limiting step in the formation of polyamines. The ...
Autoantibodies against glutamic acid decarboxylase (GAD) have been found in stiff-man syndrome, insulin dependent diabetes mellitus, and progressive cerebellar ataxia. A patient with progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results